Clover Corporation (ASX:CLV) Closed 8% Higher as Margins and Nutritional Sales Recover

Aditi Sarkar

05 September 2026 12:05 AM AEST

Clover Corporation (ASX:CLV) Closed 8% Higher as Margins and Nutritional Sales Recover

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

First-half FY26 Revenue increased 17% to AUD 44.1mn.
Gross Margin expanded to 35.6% from 27.1%.
Net profit increased to AUD 4.2mn from AUD 2.4mn.
Full-year revenue guidance remains AUD 92mn to AUD 96mn.

Clover Corporation (ASX:CLV) closed 8% higher on Friday, 4 September 2026, as investors assessed recent developments across a nutritional-ingredients producer specialising in encapsulated DHA and omega-3 oils. Best known for its DHA and omega-3 oils used in infant formula, Clover delivered an improved first-half result with expanding margins and maintained full-year guidance.

Latest Developments

The catalyst has been Clover's first-half FY26 result, which showed revenue growth, a sharp lift in gross margin and higher earnings, with the company maintaining its full-year guidance. Clover manufactures encapsulated and micro-encapsulated nutritional oils - principally DHA and omega-3 derived from fish - for infant formula and broader human-nutrition markets. New products are moving through the pipeline, and management's decision to reaffirm guidance has reassured investors that the recovery in Demand and margins is on track. For the first half of FY26, Clover reported revenue of AUD 44.1mn, up 17% from AUD 37.6mn, with gross margin expanding to 35.6% from 27.1% a year earlier. EBITDA rose to AUD 6.9mn from AUD 4.3mn, and net profit after tax increased to AUD 4.2mn from AUD 2.4mn.

Business and Investment Context

Clover is a rare profitable small cap with a differentiated, science-based product set and exposure to structural demand for nutritional ingredients. The margin recovery is significant, suggesting the Business is regaining pricing and mix benefits after a difficult period for the infant-formula sector. A pipeline of new, higher-value products offers additional growth optionality, and a return to double-digit revenue growth with widening margins is exactly the combination that can drive a re-rating in a smaller company.

Risks to Consider

Clover is exposed to the infant-formula cycle, which has been volatile, and to customer concentration, input costs and currency movements. Its growth increasingly relies on new products such as CholineXcel and Premneo, which depend on regulatory approvals and customer adoption that can be slow and uncertain. As a small cap, the stock can be relatively illiquid, and any softening in demand or margin, or a delay in new-product commercialisation, could weigh on the shares after their recent strength.

What to Watch Next

Investors will look to the full-year FY26 result to confirm whether Clover meets its AUD 92-96 million guidance and sustains the margin recovery, along with progress on the Premneo European regulatory opinion and clinical work, CholineXcel commercialisation, and ARA sales growth in the second half. Any new customer wins or capacity investment would also matter. Evidence that the new-product pipeline is converting into revenue would be the clearest driver of a further re-rating.

Outlook and Key Considerations

Clover Corporation's rally reflects a higher first-half FY26 result - 17% revenue growth, a big margin lift and higher profit - with full-year guidance maintained and a promising product pipeline. The business is profitable and differentiated, but it remains tied to the infant-formula cycle and dependent on new products clearing regulatory hurdles.

FAQs

Q: What does Clover Corporation do?

A:A nutritional-ingredients producer specialising in encapsulated dha and omega-3 oils.

Q: What supported the recent CLV share-price gain?

A:First-half FY26 revenue increased 17% to AUD 44.1mn.

Q: What is a key figure for Clover Corporation?

A:Gross margin expanded to 35.6% from 27.1%.

Q: What should investors watch next?

A:Full-year guidance, margins, premneo review, cholinexcel and ara sales.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.